BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Bästlein E, Jacobs E, Bayerdörffer E. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006;24:395-403. [PMID: 16842467 DOI: 10.1111/j.1365-2036.2006.02993.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Goh K, Chang J, Leow AH. High‐dose proton pump inhibitor and amoxicillin dual therapy with or without bismuth for 14 days as rescue therapies after Helicobacter pylori treatment failure. J Dig Dis 2020;21:566-70. [DOI: 10.1111/1751-2980.12929] [Reference Citation Analysis]
2 Brgers R, Schneider-brachert W, Reischl U, Behr A, Hiller K, Lehn N, Schmalz G, Ruhl S. Helicobacter pylori in human oral cavity and stomach. European Journal of Oral Sciences 2008;116:297-304. [DOI: 10.1111/j.1600-0722.2008.00543.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
3 Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354-361. [PMID: 29138921 DOI: 10.1007/s00535-017-1407-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 12.2] [Reference Citation Analysis]
4 Vakil N, Megraud F. Eradication Therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001. [DOI: 10.1053/j.gastro.2007.07.008] [Cited by in Crossref: 154] [Cited by in F6Publishing: 151] [Article Influence: 10.3] [Reference Citation Analysis]
5 Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, Zhang X, Cheng H. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. Helicobacter 2020;25:e12717. [PMID: 32548932 DOI: 10.1111/hel.12717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006;15:995-1016. [PMID: 16916269 DOI: 10.1517/13543784.15.9.995] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
7 Jeong MH, Chung JW, Lee SJ, Ha M, Jeong SH, Na S, Na BS, Park SK, Kim YJ, Kwon KA. [Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori]. Korean J Gastroenterol. 2012;59:401-406. [PMID: 22735872 DOI: 10.4166/kjg.2012.59.6.401] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
8 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
9 Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:331-356. [PMID: 21180581 DOI: 10.1177/1756283x09347109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
10 Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol 2014; 20(18): 5302-5307 [PMID: 24833860 DOI: 10.3748/wjg.v20.i18.5302] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
11 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Reference Citation Analysis]
12 Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52:187-190. [PMID: 19563459 DOI: 10.1111/j.1442-200x.2009.02915.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
13 Gisbert JP. Tratamientos de rescate ante el fracaso erradicador de Helicobacter pylori. Gastroenterología y Hepatología 2011;34:89-99. [DOI: 10.1016/j.gastrohep.2010.10.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
14 Öztürk K, Kurt Ö, Çelebi G, Şarlak H, Karakaya MF, Demirci H, Kılınç A, Uygun A. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol 2020;31:234-8. [PMID: 32343235 DOI: 10.5152/tjg.2020.18974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 de Korwin JD. [New recommendations for the diagnosis and the treatment of Helicobacter pylori infection]. Presse Med. 2013;42:309-317. [PMID: 23021657 DOI: 10.1016/j.lpm.2012.07.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: Current status and rational treatment options. North Clin Istanb 2020;7:87-94. [PMID: 32232212 DOI: 10.14744/nci.2019.62558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, Mitov I. Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication. Diagnostic Microbiology and Infectious Disease 2014;79:358-61. [DOI: 10.1016/j.diagmicrobio.2014.03.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
18 Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808-1825. [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x] [Cited by in Crossref: 769] [Cited by in F6Publishing: 682] [Article Influence: 51.3] [Reference Citation Analysis]
20 Gao CP, Zhou Z, Wang JZ, Han SX, Li LP, Lu H. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis. J Dig Dis. 2016;17:811-819. [PMID: 27977071 DOI: 10.1111/1751-2980.12432] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
21 Gisbert JP. Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens 2020;10:15. [PMID: 33379336 DOI: 10.3390/pathogens10010015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Siavoshi F, Saniee P, Malekzadeh R. Effective antimicrobial activity of rifabutin against multidrug-resistant Helicobacter pylori. Helicobacter 2018;23:e12531. [PMID: 30230637 DOI: 10.1111/hel.12531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Li C, Shi Y, Suo B, Tian X, Zhou L, Song Z. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis. Helicobacter 2021;26:e12816. [PMID: 34002433 DOI: 10.1111/hel.12816] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14(35): 5385-5402 [PMID: 18803350 DOI: 10.3748/wjg.14.5385] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
25 Shah SC, Tepler A, Chung CP, Suarez G, Peek RM Jr, Hung A, Roumie C, Narula N. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology 2021:S0016-5085(21)03338-2. [PMID: 34358488 DOI: 10.1053/j.gastro.2021.07.043] [Reference Citation Analysis]
26 Nishizawa T, Suzuki H, Hibi T. Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication. J Clin Biochem Nutr. 2009;44:119-124. [PMID: 19308265 DOI: 10.3164/jcbn.08-220r] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
27 Miehlke S, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Haferland C, Bästlein E, Jebens C, Zekorn C. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2008;13:69-74. [PMID: 18205669 DOI: 10.1111/j.1523-5378.2007.00588.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
28 Almeida N, Donato MM, Romãozinho JM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol 2015;15:23. [PMID: 25886722 DOI: 10.1186/s12876-015-0245-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
29 Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19:455-461. [PMID: 25231089 DOI: 10.1111/hel.12147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
30 van Zanten SV, Desai S, Best L, Cooper-Lesins G, Malatjalian D, Haldane D, Peltekian K. Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection. Can J Gastroenterol 2010;24:303-6. [PMID: 20485704 DOI: 10.1155/2010/637908] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
31 Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14396. [PMID: 30762742 DOI: 10.1097/md.0000000000014396] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 6.7] [Reference Citation Analysis]
32 Ren L, Lu H, Li HY, Zhu LY, Xu XQ, Gu LY, Ge ZZ, Li XB. New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China. J Dig Dis. 2014;15:622-627. [PMID: 25205201 DOI: 10.1111/1751-2980.12186] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
33 Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. Helicobacter 2014;19:90-7. [PMID: 24506175 DOI: 10.1111/hel.12106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
34 Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, Sorrentino D, Gasbarrini G. “Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007;39:782-789. [PMID: 17606419 DOI: 10.1016/j.dld.2007.05.016] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 4.5] [Reference Citation Analysis]
35 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M;  Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
36 Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209-221. [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 10.5] [Reference Citation Analysis]
37 Liu X, Wang H, Lv Z, Wang Y, Wang B, Xie Y, Zhou X, Lv N. Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2015;2015:415648. [PMID: 26106411 DOI: 10.1155/2015/415648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
38 Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther. 2007;26:1537-1542. [PMID: 17903237 DOI: 10.1111/j.1365-2036.2007.03531.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
39 Park HK, Lee DH, Suh S, Seo PJ, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM. Dual therapy trial using esomeprazole and amoxicillin as third-line rescue therapy for Helicobacter pylori infection. Clin Endosc 2011;44:33-7. [PMID: 22741110 DOI: 10.5946/ce.2011.44.1.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
40 Luther J, Chey WD, Saad RJ. A clinician’s guide to salvage therapy for persistent Helicobacter pylori infection. Hosp Pract (1995). 2011;39:133-140. [PMID: 21441768 DOI: 10.3810/hp.2011.02.383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Losurdo G, Iannone A, Giorgio F, Principi M, Di Leo A, Ierardi E. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: how should rifabutin be managed in rescue regimens? United European Gastroenterol J 2016;4:474-5. [PMID: 27403315 DOI: 10.1177/2050640615623697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
42 Pan XZ, Peng XW, Peng RJ. Antibiotic resistance of Helicobacter pyloriShijie Huaren Xiaohua Zazhi 2008; 16(8): 806-813 [DOI: 10.11569/wcjd.v16.i8.806] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
43 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
44 Tan B, Yang J, Young CL, Bishu S, Owyang SY, El-zaatari M, Zhang M, Grasberger H, Qian J, Kao JY. Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience. Dig Dis Sci 2018;63:437-45. [DOI: 10.1007/s10620-017-4880-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
45 Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. Korean J Helicobacter Up Gastrointest Res 2020;20:261-87. [DOI: 10.7704/kjhugr.2020.0045] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
46 Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol. 2010;5:639-648. [PMID: 20353303 DOI: 10.2217/fmb.10.25] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
47 Zullo A. The current role of dual therapy for treatment of Helicobacter pylori: back to the future? Eur J Gastroenterol Hepatol 2020;32:555-6. [PMID: 31922977 DOI: 10.1097/MEG.0000000000001654] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
48 Zhu YJ, Zhang Y, Wang TY, Zhao JT, Zhao Z, Zhu JR, Lan CH. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937115. [PMID: 33110448 DOI: 10.1177/1756284820937115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
49 Goh KL, Manikam J, Qua CS. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2012;35:1097-1102. [PMID: 22404486 DOI: 10.1111/j.1365-2036.2012.05054.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
50 Bohr UR, Malfertheiner P. Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails. Therap Adv Gastroenterol 2009;2:59-66. [PMID: 21180534 DOI: 10.1177/1756283X08100352] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
51 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212-239. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 515] [Cited by in F6Publishing: 415] [Article Influence: 103.0] [Reference Citation Analysis]
52 Papastergiou V, Mathou N, Licousi S, Evgenidi A, Paraskeva KD, Giannakopoulos A, Stavrou PZ, Platsouka E, Karagiannis JA. Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective. Ann Gastroenterol 2018;31:198-204. [PMID: 29507466 DOI: 10.20524/aog.2017.0219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
53 Gao C, Zhang D, Zhang T, Wang J, Han S, Graham DY, Lu H. PPI‐amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta‐analysis. Helicobacter 2020;25. [DOI: 10.1111/hel.12692] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
54 Kim HW, Kim GH, Cheong JY, Yang US, Park SK, Song CS, Kang DH, Song GA. H pylori eradication: A randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol 2008; 14(6): 908-912 [PMID: 18240348 DOI: 10.3748/wjg.14.908] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
55 Gao CP, Xiao X, Liu PX, Zhou Z, Li LP, Han SX. High-dose amoxicillin/esomeprazole dual therapy as a first-line therapy for Helicobacter pylori eradication. Shijie Huaren Xiaohua Zazhi 2018; 26(6): 353-359 [DOI: 10.11569/wcjd.v26.i6.353] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Nelson A, Bi Y, Harris D. Helicobacter Pylori: a comprehensive review for primary care providers. Rom J Intern Med 2021;59:112-8. [PMID: 33565305 DOI: 10.2478/rjim-2020-0043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. Helicobacter 2016;21:375-81. [PMID: 26807668 DOI: 10.1111/hel.12296] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
58 Gingold-Belfer R, Niv Y, Levi Z, Boltin D. Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1392-402. [PMID: 33037845 DOI: 10.1111/jgh.15294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
59 Jodlowski TZ, Lam S, Ashby CR. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother. 2008;42:1621-1639. [PMID: 18845620 DOI: 10.1345/aph.1l234] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
60 Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolell I, Cabriada JL, Gisbert JL, Lamas E. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35:941-947. [PMID: 22372560 DOI: 10.1111/j.1365-2036.2012.05053.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
61 Szadkowski A, Zemlak M, Muszyński J. Effectiveness of Helicobacter pylori eradication established on the basis of examination of antibiotic resistance of the bacteria. Prz Gastroenterol 2018;13:93-8. [PMID: 30002766 DOI: 10.5114/pg.2018.75821] [Cited by in F6Publishing: 1] [Reference Citation Analysis]